Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (235)	11/3/1999 10:54:00 AM
From: LLCF	Respond to of 673

Meant to do this before, but they're giving blind squirrel another chance... glia nuts bopping him on the head all week, finally doubles up @ 8.875 today: techstocks.com DAK

To: scaram(o)uche who wrote (235)	11/5/1999 10:06:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 673

Palo Alto? Well, there goes the nice "don't really need to wake up first" convenience of Berkeley....... Friday November 5, 9:09 pm Eastern Time Company Press Release SOURCE: Informed Investors, Inc. Second Annual SF Bay Area Drug Delivery Stocks Forum Saturday, November 20, 1999 in Palo Alto WHEN: 8:30 a.m.-12:15 p.m., Saturday, November 20, 1999 (Reg./Breakfast at 8) WHERE: Crowne Plaza, Palo Alto, CA 4290 El Camino Real 650-857-0787 COST TO ATTEND: $25 Prepaid: $40 At The Door (Includes Breakfast) REGISTRATION: Call 800-992-4683 or online at informedinvestors.comfocus: Drug Delivery Stocks KEYNOTE SPEAKERS: John Rende, Biotech Buyside Analyst for Weintraub Capital Management; Kellie Seringer, Biotech Analyst of Evolution Capital FORMAT: Analyst-style presentations from top executives of firms followed by Q&A AUDIOSTREAMING: Hear the Forum live (and archived) via www.informedinvestors.com PRESENTING COMPANIES: Matrix Pharmaceuticals (Nasdaq: MATX - news), Inhale Therapeutics (Nasdaq: INHL - news), Collateral Therapeutics (Nasdaq: CLTX - news), Aradigm (Nasdaq: ARDM - news), Anesta Corp. (Nasdaq: NSTA - news); SkyePharma (Nasdaq: SKYE - news) PROFILES OF KEYNOTE SPEAKERS Kellie Seringer is a principal and senior research analyst at Evolution Capital. Kellie follows the health care industry which includes biotechnology and drug delivery companies. Kellie joined Evolution Capital in December of 1997. Prior to joining Evolution Capital, she was an associate analyst covering the pharmaceutical and biotechnology industries at Montgomery Securities with John Borzilleri, MD. She also served as an associate analyst covering pharmaceuticals and drug delivery at Dean Witter Reynolds. Seringer earned her BS in Biochemistry and Genetics from Texas A&M University. John Rende is a Biotech Analyst and Partner at Wentraub Capital Management. A Bay Area native, after graduation from Claremont McKenna College in 1989, he joined America Bionetics, a biotech firm specializing in the research and design of HIV confirmatory tests. After 15 months there, he joined Wells Fargo Asset Management as an analyst and subsequently was managing more than $950 million in assets. Rende was made regional manager of the New York office of Wells Fargo Asset Management in 1994. He joined Weintraub in July 1996. CONTACT: Steve Chanecka, or Tim Quast of InformedInvestors.com, 916-448-8222, or 800-992-4683. SOURCE: Informed Investors, Inc.